Page last updated: 2024-11-07

cqp 201-403

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CQP 201-403: belongs to class of 8-aminoergolines [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14697830
SCHEMBL ID10678619
MeSH IDM0142638

Synonyms (11)

Synonym
cqp 201-403
cqp-201-403
SCHEMBL10678619
sulfamide, n,n-diethyl-n'-((8.alpha.)-6-propylergolin-8-yl)-
(6ar,10ar,9s)-9-(diethylsulfamoylamino)-7-propyl-6,6a,8,9,10,10a-hexahydro-4h-indolo(4,3-fg)quinoline
81855-35-8
cqp201-403
HA8AZ8O1QV ,
sulfamide, n,n-diethyl-n'-((8alpha)-6-propylergolin-8-yl)-
unii-ha8az8o1qv
(6ar,9s,10ar)-9-(diethylsulfamoylamino)-7-propyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic (PK)-pharmacodynamic (PD) model consisted of two kinetic compartments and an effect compartment linked to the central compartment."( Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model.
Brownell, J; Gaillard, RC; Grevel, J; Rosenthaler, J; Steimer, JL, 1986
)
0.27

Dosage Studied

ExcerptRelevanceReference
"The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization."( CQP 201-403 in Parkinson's disease: an open-label pilot study.
Glaeske, CS; Herrera, LH; Hofman, RE; Pfeiffer, RF, 1989
)
0.28
" Curve-fitting of PK and PD data provided individual parameter estimates which served to generate computer-simulated PK and PD profiles after single and multiple doses in order to: investigate the in vivo concentration-effect relationship; evaluate the consequence of dosage reduction on the steady-state PD profile; and study the robustness of the response to changes in drug potency and bioavailability."( Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model.
Brownell, J; Gaillard, RC; Grevel, J; Rosenthaler, J; Steimer, JL, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (66.67)18.7374
1990's4 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]